Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

| Crea un account

Buldini, Barbara (2008) Flow cytometry application in hematological malignancies of childhood. [Tesi di dottorato]

Full text disponibile come:

[img]
Anteprima
Documento PDF
3443Kb

Abstract (inglese)

The PhD research work was performed, for the first part (1 year) at the Pediatric Haematology-Oncology Department, Fondazione IRCCS Policlinico San Matteo, Pavia University and for the second part (2 years) at the Pediatric Haematology-Oncology Department, Padova University, two excellent setting for a specialized training in pediatric haematology-oncology. The PhD program was targeted in both a clinical and laboratory research experience in order to perform a translational research on pediatric patients affected by a wide range of hematological disorders, both malignant and non-malignant. The efforts were coordinated to study the biology and therapy of pediatric Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).


Statistiche Download - Aggiungi a RefWorks
Tipo di EPrint:Tesi di dottorato
Relatore:Basso, Giuseppe
Correlatore:Basso, Giuseppe
Dottorato (corsi e scuole):Ciclo 20 > Scuole per il 20simo ciclo > MEDICINA DELLO SVILUPPO E SCIENZE DELLA PROGRAMMAZIONE > EMATOONCOLOGIA E IMMUNOLOGIA
Data di deposito della tesi:31 Gennaio 2008
Anno di Pubblicazione:31 Gennaio 2008
Parole chiave (italiano / inglese):flow cytometry hematological malignancies hematopoietic stem cell transplantation
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/38 Pediatria generale e specialistica
Struttura di riferimento:Dipartimenti > Dipartimento di Pediatria
Codice ID:973
Depositato il:30 Ott 2008
Simple Metadata
Full Metadata
EndNote Format

Bibliografia

I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

1. Basso G, Buldini B, De Zen L, Orfao A: New methodologic approaches for immunophenotyping acute leukemia. Haematologica 2001; 86: 675-692. Cerca con Google

2. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunogical Characterization of Leukemias (EGIL). Leukemia 1995;9:1783-1786. Cerca con Google

3. Bene MC, Bernier M, Castoldi et al. Impact of immunophenotyping on management of acute leukemias. Haematologica 1999;84:1024-34. Cerca con Google

4. Bene MC, Bernier M, Casasnovasa RO al. Acute myeloid leukemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol 2001;113:737-745. Cerca con Google

5. Catovsky D, Matutes E, Buccheri V, et al. Classification of acute leukemia for the 1990s. Ann Hematol 1991; 62:16-21. Cerca con Google

6. Duggan PR, Easton D, Luider J, Auer IA. Bone marrow staging of patients with non-Hodgkin lymphoma by flow cytometry: correlation with morphology. Cancer 2000; 88 (4):894-899 Cerca con Google

7. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer M, Catovsky D. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1 H. leuk res 1998; 22 (2): 185-191. Cerca con Google

8. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997; 90:2863-92. Cerca con Google

9. Scwonzen M, Diehl V, Dellana M, Staib P. Immunophenotyping of surface antigens in acute myeloid leukemia by flow cytometry after red blood cell lysis. Leukemia Researc 31 (2007) 113- 116. Cerca con Google

10. Agresti, A. (1990) Categorical Data Analysis. New York, NY, Wiley & Sons (ed.) Cerca con Google

11. Antillon, F., Raimondi, S.C., Fairman, J., Liang, H., Nagarajan, L., Head, D.& Ribeiro, R.C. (1998) 5q- in a child with refractory anaemia with excess blasts: similarities to 5q- syndrome in adults. Cancer Genet Cytogenet, 105, 119-122. Cerca con Google

12. Bader-Meunier, B., Mielot, F., Tchemia, G., Buisine, J., Delsol, G., Duchayne, E., Lemerle, S., Leverger, G., De Lumley, L., Manel, A.M., Nathanson, M., Plantaz, D., Robert, A., Schaison, G., Sommelet, D. & Vilmer, E. (1996) Myelodysplastic syndrome in childhood: report of 49 patients from a French multicenter study. Br J Haematol, 92, 344-350. Cerca con Google

13. Benesch, M., Deeg, H.J., Wells, D. & Loken, M. (2004) Flow cytometry for diagnosis and assessment of prognosis in patients with myelodysplastic syndromes. Hematology, 9, 171– 177. Cerca con Google

14. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol, 51, 189–199. Cerca con Google

15. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann Intern Med, 103, 620–625. Cerca con Google

16. Bollag, G., Clapp, D.W., Shih, S., Adler, F., Zhang, Y.Y., Thompson, P., Lange, B.J., Freedman, M.H., McCormick, F., Jacks, T. & Shannon, K. (1996) Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet, 12, 144-148. Cerca con Google

17. Brichard, B., Vermylen, C., Scheiff, J.M., Ninane, J. & Cornu, G. (1994) Haematological disturbances during long-term valproate therapy. Eur J Pediat, 153, 378–380. Cerca con Google

18. Cantù Rajnoldi, A., Fenu, S., Kerndrup, G., van Wering, E.R., Niemayer, C.M. & Baumann, I. for the European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). (2005) Ann Hematol, 84, 429-433. Cerca con Google

19. De Zen, L., Orfao, A., Cazzaniga, G., Masiero, L., Cocito, M.G., Spinelli, M., Rivolta, A., Biondi, A., Zanesco, L. & Basso, G. (2000) Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification. Leukemia, 14, 1225-1231. Cerca con Google

20. Del Canizo, M.C., Fernandez, M.E., Lopez, A., Vidriales, B., Villaron, E., Arroyo, J.L., Ortuno, F., Orfao, A. & San Miguel, J.F. (2003) Immunophenotypic analysis of myelodysplastic syndromes. Haematologica, 88, 402-407. Cerca con Google

21. Del Poeta, G., Stasi, R., Venditti, A., Cox, C., Aronica, G., Masi, M., Bruno, A., Simone, M.D., Buccisano, F. & Papa, G. (1995) CD7 expression in acute myeloid leukemia, Leuk Lymphoma, 17, 111-119. Cerca con Google

22. Elghetany, M.T. (1998) Surface marker abnormalities in myelodysplastic syndromes. Haematologica, 83, 1104-1115. Cerca con Google

23. Font, P., Subira, D., Mtnez-Chamorro, C., Castanon, S., Arranz, E., Ramiro, S., Gli-Fernandez, J.J., Lopez-Pascual, J., Alonso, A., Perez-Saenz, M.A., Alaez, C., Renedo, M., Blas, C., Escudero, A. & Fdez-Ranada J.M. (2006) Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome. Leuk Res, 30, 957-963. Cerca con Google

24. Font, P. & Subira, D. (2008) Expression of CD7 in myelodysplastic syndromes (MDS): Is this a truly prognostic factor? Leuk Res, 32, 185-186. Cerca con Google

25. Hasle, H., Niemeyer, C.M., Chessells, G.M., Baumann, I., Bennett, J.M., Kerndrup, G. & Head, D.R. (2003) A paediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia, 17, 277–282. Cerca con Google

26. Hasle, H., Kerndrup, G. & Jacobsen, B.B. (1995) Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia, 9, 1569-1572. Cerca con Google

27. Hasle, H., Wadsworth, L.D., Massing, B.G., McBride, M. & Schultz, K.R. (1999) A populationbased study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol, 106, 1027-1032. Cerca con Google

28. Heaney, M.L. & Golde, D. (1999) Myelodysplasia. N Engl J Med, 21, 1649-1660. Cerca con Google

29. Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman JW (ed.) (2001) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon. Cerca con Google

30. Khalidi, H.S., Medeiros, L.J., Chang, K.L., Brynes, R.K., Slovak, M.L. & Arber, D.A. (1998) The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clin Pathol, 109, 211-222. Cerca con Google

31. Kussick, S.J., Fromm, J.R., Rossini, A., Li, Y., Chang, A., Norwood, T.H. & Wood, B.L. (2005) Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol, 124, 170–181. Cerca con Google

32. Lo Coco, F., De Rossi, G., Pasqualetti, D., Lopez, M., Diverio, D., Latagliata, R., Fenu, S. & Mandelli, F. (1989) CD7 positive acute myeloid leukaemia: a subtype associated with cell immaturity. Br J Hematol, 73, 480-485. Cerca con Google

33. Loken, M.R., van de Loosdrecht, A., Ogata, K., Orfao, A. & Wells, D.A. (2008) Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res, 32, 5-17. Cerca con Google

34. Luna-Fineman, S., Shannon, K.M., Atwater, S.K., Davis, J., Masterson, M., Ortega, J., Sanders, J., Steinherz, P., Weinberg, V. & Lange, B.J. (1999) Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood, 93, 459-466. Cerca con Google

35. Malcovati, L., Della Porta, M.G., Lunghi, M., Pascutto, C., Vanelli, L., Travaglino, E., Maffioli, M., Bernasconi, P., Lazzarino, M., Invernizzi, R. & Cazzola, M. (2005) Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with Myelodysplastic syndrome. Leukemia, 19, 776–783. Cerca con Google

36. Marubini, E. & Valsecchi, M.G. (1995) Analysing survival data from clinical trials and observational studies. Chichester, John Wiley & Sons (ed.). Cerca con Google

37. Maynadie, M., Picard, F., Husson, B., Chatelain, B., Cornet, Y., Le Roux, G., Campos, L., Dromelet, A., Lepelley, P., Jouault, H., Imbert, M., Rosenwadj, M., Vergé, V., Bissières, P., Raphael, M., Béné, M.C., Feuillard, J. & the Groupe d’Etude Immunologique des Leucémies (GEIL). (2002) Immunophenotypic clustering of myelodysplastic syndromes. Blood, 100, 2349–2356. Cerca con Google

38. McKenna, R.W., Washington, L.T., Equino, D.B., Picker, L.J. & Kroft, S.H. (2001) Immunophenotypic analysis of haematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow-cytometry. Blood, 98, 2498-2507. Cerca con Google

39. Miyauchi, J., Asada, M., Sasaki, M., Tsunematsu, Y., Kojima, S. & Mizutani, S. (1994) Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood, 83, 2248-2254. Cerca con Google

40. Mueller, B.U., Tannenbaum, S. & Pizzo, P.A. (1996) Bone marrow aspirates and biopsies in children with human immunodeficiency virus infection. J Pediatr Hematol Oncol, 18, 266– 271. Cerca con Google

41. Niemeyer, C.M., Duffner, U., Bender-Götze, C., Ebell, W., Hasle, H., Klingebiel, T., Kremens, B., Nurnberger, W., Vossen, J., Zecca, M., Zintl, F. & Locatelli, F. (2000) AML-Type intensive chemotherapy prior to stem cell transplantation (SCT) does not improve survival in children and adolescents with primary myelodysplastic syndromes (MDS). Blood, 96, 521a. Cerca con Google

42. Ogata, K., Kishikawa, Y., Satoh, C., Tamura, H., Dan, K. & Hayashi, A. (2006) Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood, 108, 1037-1044. Cerca con Google

43. Ogata, K., Nakamura, K., Yokose, N., Tamura, H., Tachibana, M., Taniguchi, O., Iwakiri, R., Hayashi, T., Sakamaki, H., Murai, Y., Tohyama, K., Tomoyasu, S., Nonaka, Y., Mori, M., Dan, K & Yoshida, Y. (2002) Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood, 100, 3887-3896. Cerca con Google

44. Ogata, K., Yokose, N., Shioi, Y., Ishida, Y., Tomiyama, J., Hamaguchi, H., Yagasaki, F., Bessyo, M., Sakamaki, H., Dan, K. & Kuriya S. (2001) Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia. Br J Haematol, 115, 612-615. Cerca con Google

45. Ogata, K, & Yoshida, Y. (2005) Clinical implications of blast immunophenotypes in myelodysplastic syndromes. Leuk Lymphoma, 46, 1269–1274. Cerca con Google

46. Passmore, S.J., Hann, I.M., Stiller, C.A., Ramani, P., Swansbury, G.J., Gibson, B., Reeves B.R. & Chessells, J.M. (1995) Paediatric myelodysplasia: a study of 68 children and a new prognostic scoring system: Blood, 85, 1742-1750. Cerca con Google

47. Pirruccello, S.J., Young, K.H. & Aoun, P. (2006) Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common. Am J Clin Pathol, 125, 884-894. Cerca con Google

48. Ribeiro, E., Matarraz-Sudon, S., de Santiago, M., Lima, C.S., Metze, K., Giralt, M., Saad, S.T., de Matos, A.O. & Lorand-Metze, I. (2006) Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes. Leuk Res, 30, 9-16. Cerca con Google

49. Sasaki, H., Manabe, A., Kojima, S., Tsuchida, M., Hayashi, Y., Ikuta, K., Okamura, I., Koike, K., Ohara, A., Ishii, E., Komada, Y., Hibi, S. & Nakahata, T. (2001) Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia, 15, 1713-1720. Cerca con Google

50. Shaffer, L.G. & Tommerup, N. (ed.) (2005) ISCN: An International System for Human Cytogenetic Nomenclature. Karger, Basel. Cerca con Google

51. Shikano, T., Ishikawa, Y. & Anakura, M. (1992) Myelodysplastic syndrome with partial deletion of the long arm of chromosome 5: first report of a case in a child. Acta Paediatr Jpn, 34, 539- 542. Cerca con Google

52. Steensma, D.P. & Bennet, J.M. (2006) The Myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc, 81, 104-130. Cerca con Google

53. Stewart, C.C. & Nicholson, J.K.A. (ed.) (2000) Steizer, G.T. & Goodpasture, L. Use of multiparametric flow cytometry and immunophenotyping for the diagnosis and classification of acute myeloid leukaemia. Immunophenotyping. Wiley-Liss Press, New York, NY, 215-239. Cerca con Google

54. Sternberg, A., Killick, S., Littlewood, T., Hatton, C., Peniket, A., Seidl, T., Soneji, S., Leach, J., Bowen, D., Chapman, C., Standen, G., Massey, E., Robinson, L., Vadher, B., Kaczmarski, R., Jan Mohammed, R., Clipsham, K., Carr, A. & Vyas, P. (2005) Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood, 106, 2982-2991. Cerca con Google

55. Stetler-Stevenson, M., Arthur, D.C., Jabbour, N., Xie, X.Y., Molldrem, J., Barrett, A.J., Venzon, D. & Rick, M.E. (2001) Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood, 98, 979–87. Cerca con Google

56. Tartaglia, M., Niemeyer, C.M., Song, X., Buechner, J., Hählen, K., Hasle, H., Jung, A., Licht, J.D. & Gelb, B.D. (2003) Somatic PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet, 34, 148-150. Cerca con Google

57. Tavil, B., Cetin, M. & Tuncer, M. (2006) CD34/CD117 positivity in assessment of prognosis in children with myelodysplastic syndrome. Leuk Res, 30, 222-224. Cerca con Google

58. Valent, P., Horny, H.P., Bennett, J.M., Fonatsch, C., Germing, U., Greenberg, P., Haferlach, T., Haase, D., Kolb, H.J., Krieger, O., Loken, M., van de Loosdrecht, A., Ogata, K., Orfao, A., Pfeilstöcker, M., Rüter, B., Sperr, W.R., Stauder, R. & Wells, D.A. (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res, 31, 727-736. Cerca con Google

59. van de Loosdrecht, A.A., Westers, T.M., Westra, A.H., Drager, A.M., van der Velden, V.H.J. & Ossenkoppele, G.J. (2007) Identification of distinct prognostic subgroups in low and intermediate-1 risk myelodysplastic syndromes by flow cytometry. Blood [in press]. Cerca con Google

60. Webb, D.K.H., Passmore, S.J., Hann, I.M., Harrison, G., Wheatley, K. & Chessells, J.M. (2002) Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEB-t) in Great Britain 1990–99. Br J Haematol, 117, 33–39. Cerca con Google

61. Wells, D.A., Benesch, M., Loken, M.R., Vallejo, C., Myerson, D., Leisenring, W.M. & Deeg, J. (2003) Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in Myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood, 102, 394–403. Cerca con Google

62. Buonamici, S., Ottaviani, E., Testoni, N., Montefusco, V., Visani, G., Bonifazi, F., Amabile, M., Terragna, C., Ruggeri, D., Piccaluga, P.P., Isidori, A., Malagola, M., Baccarani, M., Tura, S. & Martinelli, G. ( 2002) Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood, 99, 443– 449. Cerca con Google

63. Coustan-Smith E., Behm, F.G., Sanchez, J., Boyett, J.M., Hancock, M.L., Raimondi, S.C., Rubnitz, J.E., Rivera, G.K., Sandlund, J.T., Pui, C.H. & Campana, D. (1998) Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet, 351, 550– 554. Cerca con Google

64. Coustan-Smith E., Sancho, J., Hancock, M.L., Boyett, J.M., Behm, F.G., Raimondi, S.C., Sandlund, J.T., Rivera, G.K., Rubnitz, J.E., Ribeiro, R.C., Pui, C.H. & Campana, D. (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 96, 2691– 2696. Cerca con Google

65. Campana D., Coustan-Smith E. (2002) Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Practice and Research Clinical Haematology, 15, 1– 19. Cerca con Google

66. Coustan-Smith E., Sancho, J., Behm, F.G., Hancock, M.L., Razzouk, B.I., Ribeiro, R.C., Rivera, G.K., Rubnitz, J.E., Sandlund, J.T., Pui, C.H. & Campana, D. (2002a) Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood, 100, 52– 58. Cerca con Google

67. Coustan-Smith E., Sancho, J., Hancock, M.L., Razzouk, B.I., Ribeiro, R.C., Rivera, G.K., Rubnitz, J.E., Sandlund, J.T., Pui, C.H. & Campana, D. (2002b) Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood, 100, 2402. Cerca con Google

68. Estey, E.H., Shen, Y. & Thall, P.F. (2000) Effect of time to complete remission on subsequent survival and disease- free survival time in AML, RAEB-t, and RAEB. Blood, 95, 72– 77. Cerca con Google

69. Forestier E, Heim S, Blennow E, et al: Cytogenetic abnormalities in childhood acute myeloid leukaemia: A Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001. Br J Haematol 121:566-577, 2003 Cerca con Google

70. Garg M, Moore H, Tobal K, et al: Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukemia. Br J Haematol 123:49-59, 2003 Cerca con Google

71. Grimwade, D. ( 1999) The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. British Journal of Haematology, 106, 591– 613 Cerca con Google

72. Guerrasio, A., Pilatrino, C., De Micheli, D., Cilloni, D., Serra, A., Gottardi, E., Parziale, A., Marmont, F., Diverio, D., Divona, M., Lo, C.F. & Saglio, G. (2002) Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Cerca con Google

73. Kern, W., Haferlach, T., Schoch, C., Loffler, H., Gassmann, W., Heinecke, A., Sauerland, M.C., Berdel, W., Buchner, T. & Hiddemann, W. (2003) Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood, 101, 64– 70. Cerca con Google

74. Lo Coco, F., Diverio, D., Falini, B., Biondi, A., Nervi, C. & Pelicci, P.G. ( 1999) Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood, 94, 12– 22. Cerca con Google

75. Macedo, A., Orfao, A., Gonzalez, M., Vidriales, M. B., Lopez-Berges, M. C. and Martinez, A (1995) Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia 9 , pp. 993-998. Cerca con Google

76. Oehler VG, Radich JP: Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia. Curr Oncol Rep 5:426-435, 2003 Cerca con Google

77. Ogawa H, Tamaki H, Ikejame K, et al: The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101:1698-1704, 2003 Cerca con Google

78. Ostergaard M, Olesen LH, Hasle H, et al: WT1 gene expression: An excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients—results from a singlecenter study. Br J Haematol 125:590-600, 2004 Cerca con Google

79. Perel Y, Auvrignon A, Leblanc T, et al: Treatment of childhood acute myeloblastic leukaemia: Dose intensification improves treatment outcome and maintenance therapy is no benefit27 multicenter studies of the French LAME (Leucémie aiguë Myéloblastique Enfant) Cooperative Group. Leukemia 19:2082-2089, 2005 Cerca con Google

80. Raimondi SC, Chang MN, Ravindranath Y, et al: Chromosomal abnormalities in 478 children with acute myeloid leukemia clinical characteristics and treatment outcome in a cooperative pediatric oncology group study: POG 8821. Blood 94:3707-3716, 1999 Cerca con Google

81. Schmid D, Heinze G, Linnerth B, et al: Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 11:639-643, 1997 Cerca con Google

82. Sievers, E.L., Lange, B.J., Buckley, J.D., Smith, F.O., Wells, D.A., Daigneault-Creech, C.A., Shults, K.E., Bernstein, I.D. & Loken, M.R. ( 1996) Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. Journal of the National Cancer Institute, 88, 1483– 1488. Cerca con Google

83. Sievers EL, Lange BJ, Alonzo TA, et al: Immunophenotypic evidence of leukaemia after induction therapy predicts relapse: Results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukaemia. Blood 101:3398-3406, 2003 Cerca con Google

84. Stevens RF, Hann IM, Wheatley K, et al: Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: Results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol 101:130-140, 1998 Cerca con Google

85. Szczepanski T, Orfao A, van der Velden VH, et al: Minimal residual disease in leukaemia patients. Lancet Oncol 2:409-417, 2001 Cerca con Google

86. Tobal, K., Newton, J., Macheta, M., Chang, J., Morgenstern, G., Evans, P.A., Morgan, G., Lucas, G.S. & Liu, Y.J. ( 2000) Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood, 95, 815– 819. Cerca con Google

87. Venditti, A., Buccisano, F., Poeta, G Del, Maurillo, L., Tamburini, A. and Cox, C. (2000) Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 96 , pp. 3948-3952. Cerca con Google

88. Walker, H. (1999) A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. British Journal of Haematology, 107, 69– 79. Cerca con Google

89. Woods WG, Neudorf S, Gold S, et al: A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: A report from the children's cancer group. Blood 97:56-62, 2001 Cerca con Google

90. Lowenberg B, Downing JR, Burnett A.: Acute myeloid leukemia. N Engl J Med 341:1051-1062, 1999 Cerca con Google

91. Grimwade D, Howe K, Langabeer S, et al: Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party. Br J Haematol 94:557-573, 1996 Cerca con Google

92. Kalwinsky DK, Raimondi SC, Schell MJ, et al: Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J Clin Oncol 8:75-83, 1990 4. Kiyoi H, Naoe T, Nakano Y, et al: Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93:3074-3080, 1999 Cerca con Google

93. Kottaridis PD, Milligan DW, Chopra R, et al: In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96:2419-2425, 2000 Cerca con Google

94. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335, 2002 Cerca con Google

95. Leith CP, Kopecky KJ, Chen IM, et al: Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94:1086-1099, 1999 Cerca con Google

96. Steinbach D, Sell W, Voigt A, et al: BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16:1443-1447, 2002 Cerca con Google

97. Campos L, Rouault JP, Sabido O, et al: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091-3096, 1993 Cerca con Google

98. Kohler T, Schill C, Deininger MW, et al: High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). Leuk. 16:22-29, 2002 Cerca con Google

99. Cazzaniga G, Dell'oro MG, Mecucci C, et al: Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood (in press) Cerca con Google

100. Tartaglia M, Martinelli S, Iavarone I, et al: Somatic PTPN11 mutations in childhood acute myeloid leukaemia. Br J Haematol 129:333-339, 2005 Cerca con Google

101. Schoch C, Kohlmann A, Schnittger S, et al: Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A 99:10008-10013, 2002 Cerca con Google

102. Ross ME, Mahfouz R, Onciu M, et al: Gene expression profiling of pediatric acute myelogenous leukemia. Blood 104:3679-3687, 2004 Cerca con Google

103. Yagi T, Morimoto A, Eguchi M, et al: Identification of a gene expression signature associated with pediatric AML prognosis. Blood 102:1849-1856, 2003 Cerca con Google

104. Bullinger L, Dohner K, Bair E, et al: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. NEJ Med 350:1605-1616, 2004 Cerca con Google

105. Valk PJ, Verhaak RG, Beijen MA, et al: Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350:1617-1628, 2004ù Cerca con Google

106. De Zen L, Bicciato S, te Kronnie G, Basso G.: Computational analysis of flow-cytometry antigen expression profiles in childhood acute lymphoblastic leukemia: an MLL/AF4 identification. Leukemia 17:1557-1565, 2003 Cerca con Google

107. Basso G, Buldini B, De Zen L, Orfao A.: New methodologic approaches for immunophenotyping acute leukemias. Haematologica 86:675-692, 2001 Cerca con Google

108. De Zen L, Orfao A, Cazzaniga G, et al: Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification. Leukemia 14:1225-1231, 2000 Cerca con Google

109. Mitelman F.: Chromosomes, genes, and cancer. CA Cancer J Clin 44:133-135, 1994 Cerca con Google

110. van Dongen JJ, Macintyre EA, Gabert JA, et al: Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13:1901-1928, 1999 Cerca con Google

111. Frascella E, Rondelli R, Pigazzi M, et al: Clinical features of childhood acute myeloid leukaemia with specific gene rearrangements. Leukemia 18:1427-1429, 2004 Cerca con Google

112. Eisen MB, Spellman PT, Brown PO, Botstein D.: Cluster analysis and display of genomewide expression patterns. Proc Natl Acad Sci USA 95:14863-14868, 1998 Cerca con Google

113. The R project for statistical computing [http://www.R-project.org] Vai! Cerca con Google

114. Kaplan EL, Meier P.: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958 Cerca con Google

115. Hurwitz CA, Raimondi SC, Head D, et al: Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 80:3182-3188, 1992 Cerca con Google

116. Ferrara F, Di Noto R, Annunziata M, et al: Immunophenotypic analysis enables the correct prediction of t(8;21) in acute myeloid leukaemia. Br J Haematol 102:444-448, 1998 Cerca con Google

117. Re F, Arpinati M, Testoni N, et al: Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage. Exp Hematol 30:126-134, 2002 Cerca con Google

118. Ramaswamy S, Tamayo P, Rifkin R, et al: Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA 98:15149-15154, 2001 Cerca con Google

119. Ross DT, Scherf U, Eisen MB, et al: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24:227-235, 2000 Cerca con Google

120. Tallman MS, Kim HT, Paietta E, et al: Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group. J Clin Oncol 22:1276-1286, 2004 Cerca con Google

121. Casasnovas RO, Slimane FK, Garand R, et al: Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia 17:515-527, 2003 34. Hrusak O, Porwit-MacDonald A.: Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 16:1233-1258, 2002 Cerca con Google

122. Paietta E, Goloubeva O, Neuberg D, et al: A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Cytometry B Clin Cytom 59:1-9, 2004 Cerca con Google

123. Philip A. Pizzo, David G. Poplack: Principles and Practice of Pediatric Oncology (ed. 4) Lippincott Williams & Wilkins, 2005 Cerca con Google

124. Primo D, Tabernero MD, Perez JJ, Rasillo A, Sayagues JM, Espinosa AB, Lopez-Berges MC, Garcia-Sanz R, Gutierrez NC, Hernandez JM, Romero M, Osuna CS, Giralt M, Barbon M, San Miguel JF, Orfao A: Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia 2005; 19: 713-720. Cerca con Google

125. Tabernero MD, Bortoluci AM, Alaejos I, Lopez-Berges MC, Rasillo A, Garcia-Sanz R, Garcia M, Sayagues JM, Gonzalez M, Mateo G, San Miguel JF, Orfao A: Adult precursor B-ALL with BCRABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34 CD13 and CD38 expression. Leukemia 2001; 15: 406-414. Cerca con Google

126. Braylan RC, Borowitz MJ, Davis BH, Stelzer GT, Stewart CC. US-Canadian consensus on the immunophenotypic analysis of hematologic neoplasia by flow cytometry. Cytometry 1997; 30:213. Cerca con Google

127. De Zen L, Orfao A, Cazzaniga G, Masiero L, Cocito MG, Spinelli M, Rivolta A, Biondi A, Zanesco L, Basso G: Quantitative multiparametric imunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification. Leukemia 2000; 14: 1225-1231. Cerca con Google

128. Benè MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van’t Veer MB. Proposals for the immunological classification of acute leukemias. European Group for the immunological characterization of leukemias (EGIL). Leukemia 1995; 9:1783-1786 Cerca con Google

129. Schrappe M, Aricò M, Harbott J: Philadelphia chromosome positive childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favourable treatment outcome. Blood 1998; 92: 2730-2741. Cerca con Google

130. Cazzaniga G, Lanciotti M, Rossi V, Di Martino D, Aricò M, Valsecchi MG: Prospective molecular monitoring of BCR/ABL transcripts in children with Ph+ acute lymphoblastic leukemia unravels differences in treatment response. Br J Haematol 2002; 19: 445-453. Cerca con Google

131. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukemia on MRC trial UKALL XA. MRC Adult Leukaemia Worting Party. Br J Haematol 1997; 96:601-610. Cerca con Google

132. Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001;15:21-36 Cerca con Google

133. Aricò M, Valsecchi MG, Camitta B, Schrappe M, Chessels J, Baruchel A, Gaynon P, Silverman L, Janka-Shaub G, Kamps W, Pui CH, Masera G: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Eng J Med 2000; 342: 998- 1006. Cerca con Google

134. Yeoh EJ, Ross ME, Shurtleff SA: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukaemia by gene expression profiling. Cancer Cell 2002; 1: 133. Cerca con Google

135. Hofmann WK, de Vos S, Elashoff D, Gschaimeier H, Hoelzer D, Koeffler HP et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles study. Lancet 2002; 359: 481-486. Cerca con Google

136. Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, Wurster-Hill DH, Sobol RE, Schiffer C, Bloomfield CD. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992; 80:2983-90 Cerca con Google

137. Melo JV, Myint H, Galton DA, Golman JM. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 1994; 8:208-211 Cerca con Google

138. Ravandi F, Cortes J, Albitar M et al. Chronic myelogenous leukaemia with p185BCR-ABL expression: characteristics and clinical significance. Br J Haematol. 1999; 107:581-586. Cerca con Google

139. Suryanarayan K, Hunger SP, Kohler S, Carroll AJ, Crist W, Link MP, Cleary ML. Consistentt involvement of the bcr gene by 9;22 breakpoins in pediatric acute leukemias. Blood 1991; 77, 324-330 Cerca con Google

140. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96, 3343-3356 Cerca con Google

141. Maurer J, Janssen JW, Thiel E, van Denderen J, Ludwig WD, Aydemir U, Heinze B, Fonatsch C, Harbott J, Reiter A, Riehm H, Hoelzer D, Bartram CR. Detection of chimeric BCR/ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 1991; 337, 1055- 1059 Cerca con Google

142. van Dongen JJM, Macintyre EA, Gabert JA et al: Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928. Cerca con Google

143. Borowitz MJ, Rubnitz J, Nash M, Pullen DJ, Camitta B. Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group. Leukemia 1998; 12:1764-1770 Cerca con Google

144. Borowitz MJ, Hunger SP, Carroll AJ, Shuster JJ, Pullen DJ, Steuber CP, Clearly ML. Predictability of the t(1;19) (q23;p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis. A Pediatric Oncology Group study. Blood 1993; 82:1086-1091 Cerca con Google

145. Tritz D, Pettigrew A, Talkington S, Smith L, jennings CD. Association of Cd15 expression and 11q23 translocation in acute leukemias. Mol Pathol 1995; 8:122-129. Cerca con Google

146. Pui CH. Acute lymphoblastic leukemias with the t (4;11)(q21;q23). Leuk Lymphoma 1992;7:173- 179 Cerca con Google

147. Pui CH, Raimondi SC, Head DR, Schell MJ, Rivera GK, Mirro J jr, Crist WM, Behm FG. Characterization of childhood acute lymphoblastic leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood 1991; 78:1327-1337 Cerca con Google

148. Armstrong SA, Staunton SE, Silverman LB, Pieters R, den Boer ML, Minden MD: MLL translocation specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41-47. Cerca con Google

149. De Zen L, Bicciato S, te Kronnie G, Basso G: Computational analysis of flow-cytometry antigen expression profiles in childhood acute lymphoblastic leukemia: an MLL/AF4 identification. Leukemia 2003; 17: 1557-1565. Cerca con Google

150. Veltroni M, De Zen L, Sanzari MC, Maglia O, Dworzak MN, Ratei R, Biondi A, Basso G, Gaipa G: Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: inplications for the detection of minimal residual disease in acute lymphocitic leukemia. Leukemia 2003; 88(11): 1245-1252 Cerca con Google

151. Nachman JB, Heerema NA, Sather H, Camitta B, Forestier E, Harrison CJ, Dastugue N, Schrappe M, Pui CH, Basso G, Silverman LB, Janka-Schaub GE: Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007; 110: 1112-1115. Cerca con Google

152. Copelan EA. Hematopoietic stem cell transplantation. N Engl J Med 2006; 354: 1813–1826. Cerca con Google

153. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex linked lymphpenicc immunological deficency. Lancet 1968; ii:1366-9 Cerca con Google

154. Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM. Bone-marrow tranplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 1968; ii 1364-6 Cerca con Google

155. Burnet M. Self and not-self. Melbourne: University Press: 1970. Cerca con Google

156. Locatelli F, Burgio GR. Transplant of hematopoietic stem cells in chilhood: where we are and where we are going. Haematologica 1998 Jun; 83 (6): 550-63 Cerca con Google

157. Anasetti C, Amos D, Beatty PG, et al. Effect of the HLA compatibility on engrafment of bone marrow transplants in patients with leucemia or lymphoma. N Engl J Med 1989; 320:197-204 Cerca con Google

158. Anasetti C, Hansen J. Effect of the HLA incompatibility in marrow transplantation from unrelated HLA-mismatched related donors. Transf Sci 1994; 14:221-30. Cerca con Google

159. Burgio GR, Nespoli L, Porta F, Bonett F. Bone marrow transplantation in children: 20 years after its first successful application. Haematologica 1988; 73:437-43 Cerca con Google

160. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J med 1989; 321: 1174-8. Cerca con Google

161. Miano M, Labopin M, Hartmann O, Angelucci E, Cornish J, Gluckman E, Locatelli F, Fischer A, Egeler RM, Or R, Peters C, Ortega J, Veys P, Bordigoni P, Iori AP, Niethammer D, Rocha V, Dini G; Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation. Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2007 Jan;39(2):89-99. Cerca con Google

162. Caplan AI. The mesengenic process. Clin.Plast.Surg. 1994; 21:429-435. Cerca con Google

163. Prockop DJ. Marrow stromal cells as a stem cells from nonhematopoietic tissues. Science 1997;276:71-74. Cerca con Google

164. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147. Cerca con Google

165. Bianco P, Gehron Robey P. Marrow stromal stem cells. J Clin Invest 2000;105:1663- 1668. Cerca con Google

166. Bartolomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48. Cerca con Google

167. Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389-397. Cerca con Google

168. Maccario R, Podestà M, Moretta A, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favours the differentiation of CD4+ T-cell subsets expressing regulatory/suppressive phenotype. Haematologica 2005; 90 (4): 516-525. Cerca con Google

169. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical use. Exp Hermat 2000; 28: 875-884. Cerca con Google

170. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Bioch & Cell Biol 2004; 36: 568-584. Cerca con Google

171. Jorgensen C, Gordeladze J, Noel D. Tissue engineering through autologous mesenchymal stem cells. Curr Opin Biotechnol 2004; 15: 406-410. Cerca con Google

172. Koc ON, Gerson SL, Cooper BM et al. Rapid hematopoietic recovery after co-infusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18:307-316. Cerca con Google

173. Lazarus HM, Koc ON, Devine SM et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transpl 2005; 11: 389-398. Cerca con Google

174. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe graft-versus-host disease with third party haploidentical mesenchymal stem cells. The Lancet 2004; 363: 1439-1441. Cerca con Google

175. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005;11:389-39. Cerca con Google

176. Frassoni F, Labopin M, Bacigalupo A, et al. Expanded mesenchymal stem cells (MSC), co-infused with HLA-identical hematopoietic stem cell transplant, reduce acute and chronic graft versus host disease: a matched pair analysis [abstract]. Bone Marrow Transplant. 2002; 29 (Suppl 2):75. Cerca con Google

177. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309-313. Cerca con Google

178. Horwitz EM, Gordon PL, Koo WKK, et al. Isolated allogeneic bone marrow derived mesenchymal stem cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. PNAS 2002; 99: 8932-8937. Cerca con Google

179. Le Blanc K, Gotherstrom C, Ringden O, et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005; 79:1607-1614. Cerca con Google

180. Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM and Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy and Hurler syndrome. Bone Marrow Transpl 2002; 30: 215.222. Cerca con Google

181. Almeida-Porada G, Flake AW, Glimp HA and Zanjani ED. Cotransplantation of stroma results in enhancement of engraftment and early expression of donor hematopoietic stem cells in utero. Exp Hematol. 1999;27:1569-1575. Cerca con Google

182. Devine SM, Cobbs C, Jenning M et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into non-human primates. Blood 2003; 101: 2999-3001. Cerca con Google

183. Simmons PJ, Przepiorka D, Thomas ED and Torok-Storb B. Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature 1987;328 (6129):429-432.Devine SM, Hoffman R. Role of mesenchymal stem cells in hematopoietic stem cell transplantation. Curr Opinion Hemat 2000;7:358-363. Cerca con Google

184. Cilloni D, Carlo-Stella C, Falzetti F, et al. Limited engraftment capacity of bone marrowderived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. Blood 2000;96:3637-3643. Cerca con Google

185. Koc ON, Peters C, Aubourg P, et al. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp Hematol 1999;27:1675-1681. Cerca con Google

186. Stute N, Fehse B, Schroder J, et al. Human mesenchymal stem cells are not of donor origin in patients with severe aplastic anemia who underwent sex-mismatched allogeneic bone marrow transplant. J Hematother Stem Cell Res 2002;11:977-984. Cerca con Google

187. Dickhut A, Schwerdtfeger R, Kuklick L et al. Mesenchymal stem cells obtained after bone marrow transplantation or peripheral blood stem cell transplantation originate from host tissue. Ann Hematol 2005; 84 (11): 722-727. Cerca con Google

188. Horwitz EM, Prockop DJ, Gordon PL, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001;97:1227- 1231. Cerca con Google

189. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000;109:235-242. Cerca con Google

190. Bieback K, Kern S, Kluter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004; 22 (4): 625-634. Cerca con Google

191. Wexler SA, Donaldson C, Dennung-Kendall P, et al. Adult bone marrow is a rich source of human mesenchymal stem cells but umbilical cord and mobilized adult blood are not. Br J Haematol 2003;12:368-374. Cerca con Google

192. Kang TJ, Yeom JE, Lee HJ, et al. Growth kinetics of human mesenchymal stem cells from bone marrow and umbilical cord blood. Acta Haematol 2004;112:230-233. Cerca con Google

193. Kogler G, Sensken S, Airey JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004; 200 (2): 123-135. Cerca con Google

194. Lee OK, Kuo TK, Chen W-M, et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004; 103: 1669-1675. Cerca con Google

195. Friedenstein AJ, Deriglazova UF, Kulagina NN, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974;2:83-92. Cerca con Google

196. Castro-Malaspina H, Gay RE, Resnick G, et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 1980;56:289-301. Cerca con Google

197. Pugatsch T, Oppenheim A, Slavin S. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant. 1996;17:273-275. Cerca con Google

198. Allen RC, Graves G, Budowle B. Polymerase chain reaction amplification products separated on rehydratable polyacrylamide gels and stained with silver. Biotechniques 1989;7:736-744. Cerca con Google

199. Awaya N, Rupert K, Bryant E and Torok-Storb B. Failure of adult marrow-derived stem cells to generate marrow stroma after successful hematopoietic stem cell transplantation. Exp Hematol 2002;30:937-942. Cerca con Google

200. Rieger K, Marinets O, Fietz T, et al. Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. Exp Hematol 2005;33:605-611. Cerca con Google

201. Minjun Y, Xiao Z, Shen L and Li L. Mid-trimester fetal blood-derived adherent cells share characteristics similar to mesenchymal stem cells but full-term umbilical cord blood does not. British J Hematol 2003; 124: 666-675. Cerca con Google

202. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, Warnock DW: Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001, 33: 641-647. Cerca con Google

203. Marr K, Carter R, Crippa F, Wald A, Corey L: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34: 909-907. Cerca con Google

204. Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, Fridkin SK, Pappas PG, Warnock DW : Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005, 43(S1):S49-S58. Cerca con Google

205. Lin SJ, Schranz J, Teusch SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001, 32: 358-366. Cerca con Google

206. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347: 408-415. Cerca con Google

207. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ; Caspofungin Salvage Aspergillosis Study Group: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004, 39: 1563-1571. Cerca con Google

208. Arikan S, Lozano-Chiu M, Paetznick V: In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002, 46: 245-247. Cerca con Google

209. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF: Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002, 46: 2564-2568 . Cerca con Google

210. Petraitis V, Petraitiene R, Sarafandi AA, Kelaher AM, Lyman CA, Casler HE, Sein T, Groll AH, Bacher J, Avila NA, Walsh TJ: Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003, 187: 1834-1843. Cerca con Google

211. Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA: Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003, 97: 1025-1032. Cerca con Google

212. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad II :Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003, 98: 292-299. Cerca con Google

213. Rubin MA, Carroll KC, Cahill BC: Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 2002, 34: 1160. Cerca con Google

214. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39: 797-802. Cerca con Google

215. Dinser R, Grgic A, Kim Y-J, Pfreundschuh M, Schubert J: Successful treatment of disseminated aspergillosis with the combination of voriconazole, caspofungin, granulocyte transfusions, and surgery followed by allogeneic blood stem cell transplantation in a patient with primary failure of an autologous stem cell graft. Eur J Haematol 2005, 74: 438-441. Cerca con Google

216. Cesaro S, Toffolutti T, Messina C, Calore E, Alaggio R, Cusinato R, Pillon M, Zanesco L: Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol 2004, 73: 50-55. Cerca con Google

217. Elanjikal Z, Sorensen J, Schmidt H, Dupuis W, Tintelnot K, Jautzke G, Klingebiel T, Lehrnbecher T: Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis. Pediatr Infect Dis 2003, 22: 653-656. Cerca con Google

218. Pancham S, Hemmaway C, New H, Albert E, Dokal I, Roberts IA, McCloy M: Caspofungin for invasive fungal infections:combination treatment with liposomal amphotericin B in children undergoing hematopoietic stem cell transplantation. Pediatr Transplantation 2005, 9: 254-257. Cerca con Google

219. Groll AH, Attarbaschi A, Schuster FR, Herzog N, Grigull L, Dworzak MN, Beutel K, Laws HJ, Lehrnbecher T: Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. J Antimicrob Chemother 2006, 57: 527-535. Cerca con Google

220. Castagnola E, Cesaro S, Giacchino M, Livadiotti S, Tucci F, Zanazzo G, Caselli D, Caviglia I, Parodi S, Rondelli R, Cornelli PE, Mura R, Santoro N, Russo G, De Santis R, Buffardi S, Viscoli C, Haupt R, Rossi MR: Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J 2006, 25: 634-639. Cerca con Google

221. Viscoli C, Castagnola E, Caniggia M, De Sio L, Garaventa A, Giacchino M, Indolfi P, Izzi GC, Manzoni P, Rossi MR, Santoro N, Zanazzo GA, Masera G: Italian guidelines for the management of infectious complications in pediatric oncology: empirical antimicrobial therapy of febrile neutropenia. Oncology 1998, 55: 489-500. Cerca con Google

222. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34: 730-751. Cerca con Google

223. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999, 340: 764-771. Cerca con Google

224. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ, Gibson BE: A randomized comparison of liposomal versus conventional amphotericin B for treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997, 98: 711-718. Cerca con Google

225. Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L, Lopez J, Couillault G, Piard F, Vagner O, Guy H: Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001, 19: 253-259. Cerca con Google

226. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M: Screening for circulating galactomannan as a non-invasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001, 97: 1604-1610. Cerca con Google

227. Marr KA, Balajee A, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ: Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect the performance. J Infect Dis 2004, 190: 641-649. Cerca con Google

228. The EBMT Handbook. Haemopoietic stem cell transplantation. European Group for Blood and Marrow Transplantation and European School of Haematology. Edited by Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T. Genova: Forum Service Editore, 2004. Cerca con Google

229. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002, 34: 7-14. Cerca con Google

230. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34: 563-571. Cerca con Google

231. Steinbach WJ: Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Curr Drug Targets Infect Disord 2005, 5: 203-210. Cerca con Google

232. Chandrasekar PH, Cutright JL, Manavathu EK: Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin Microbiol Infect Dis 2004, 10: 922-950. Cerca con Google

233. Baddley JW, Pappas PG: Antifungal combination therapy: clinical potential. Drugs 2005, 65: 1461-1480. Cerca con Google

234. Kontoyiannis DP, Lewis RE: Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 2004, 126: 165-175. Cerca con Google

235. Marr K. Combination antifungal therapy: where are we now, and where are we going? Oncology 2004, 18(S7): 24-29 . Cerca con Google

236. Cornelly AO, Maertens J, Bresnik M, Herbrecht R: Liposomal amphotericin B (L-AMB) as initial therapy for filamentous fungal infections (IFFI): a randomized, prospective trial of a high loading regimen vs standard dosing (Ambiload trial). Blood 2005, 106(II):abs3222. Cerca con Google

237. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ: Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy of in 556 cases. Clin Infect Dis 1998, 26: 1383-1396. Cerca con Google

238. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ; Caspofungin Salvage Aspergillosis Study Group: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory or intolerant of conventional antifungal therapy. Clin Infect Dis 2004, 39: 1563-1571. Cerca con Google

239. Kartsonis NA, Saah AJ, Lipka J, Taylor AF, Sable CA: Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005, 50: 196-205. Cerca con Google

240. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR: Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Ped Infect Dis J 2002, 21: 240-248. Cerca con Google

241. Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH, Killar J, Taylor A, Kartsonis N, Patterson TF: Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006, 107:2888-2897 Cerca con Google

242. Abbassi S, Shenep JL, Hughes WT, Flynn PM: Aspergillosis in children with cancer: a 34- year experience. Clin Infect Dis 1999, 29: 1210-1219. Cerca con Google

243. Cordonnier C, Ribaud P, Herbrecht R, Milpied N, Valteau-Couanet D, Morgan C, Wade A; Societe Francaise de Greffe de Moelle et de Therapie Cellulaire: Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French Transplantation Centers. Clin Infect Dis 2006, 42: 955- 963. Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record